Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-

Date publication

mai 2021

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CHARON-BARRA Céline

Tous les auteurs :
Schöffski P, Toulmonde M, Estival A, Marquina G, Dudzisz-Śledź M, Brahmi M, Steeghs N, Karavasilis V, de Haan J, Wozniak A, Cousin S, Domènech M, Bovée JVMG, Charon-Barra C, Marreaud S, Litière S, De Meulemeester L, Olungu C, Gelderblom H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34062484

Résumé

EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival.

Mots clés

Chemotherapy, Fibroblast growth factor receptor, Ifosfamide, Nintedanib, Oral anticancer treatment, Soft tissue sarcoma, Tyrosine kinase inhibitor, Vascular endothelial growth factor receptor

Référence

Eur J Cancer. 2021 May 29;152:26-40